Compare Stocks Compare stocks with our powerful stock comparison tool. Analyze fundamentals, price performance, and key financial indicators to make informed investment decisions. Our tool lets you compare up to ten stocks side by side based on Performance Charts, Price & Volume, MarketRank™, Analyst Ratings, Sales & Book Value, Profitability & Earnings, Dividends, Debt, Ownership, Headlines, and more. Simply enter up to ten stock symbols (e.g., BAC, JPM, WFC, C, GS) to get started and uncover top investment opportunities. Stocks to Compare Sections All Sections Selected Performance Chart Price & Volume MarketRank Analyst Ratings Sales & Book Value Profitability & Earnings Dividends Debt Ownership Miscellaneous Headlines About Compare NASDAQ:ENTONASDAQ:GLMDNASDAQ:QLGNNASDAQ:VIRX On This Page Performance ChartPrice & VolumeMarketRank™Analyst RatingsSales & Book ValueProfitability & EarningsDividendsDebtOwnershipMiscellaneousHeadlinesAbout Comparison Ideas Stock Ideas Comparative Price Performance Over Time1 day7 days30 days90 days365 daysCompare Price & VolumeCompanyCurrent Price50-Day Moving Average52-Week RangeMarket CapBetaAvg. VolumeToday's VolumeENTOEntero Therapeutics$0.48+3.2%$0.42$0.19▼$2.29$2.31M0.85718,562 shs138,459 shsGLMDGalmed Pharmaceuticals$1.78+6.6%$1.43$1.15▼$23.80$2.94M0.511.31 million shs592,315 shsQLGNQualigen Therapeutics$3.74+6.6%$3.65$2.85▼$29.44$2.75M0.01111,328 shs73,350 shsVIRXViracta Therapeutics$0.02-11.6%$0.02$0.01▼$0.65$608K1.071.07 million shs30,059 shsThese 7 Stocks Will Be Magnificent in 2025Discover the next wave of investment opportunities with our report, 7 Stocks That Will Be Magnificent in 2025. Explore companies poised to replicate the growth, innovation, and value creation of the tech giants dominating today's markets.Get This Free ReportCompare Price PerformanceCompany1-Day Performance7-Day Performance30-Day Performance90-Day Performance1-Year PerformanceENTOEntero Therapeutics+3.15%-15.09%+17.89%-7.75%-75.66%GLMDGalmed Pharmaceuticals+6.27%+5.95%+39.06%-22.27%-55.77%QLGNQualigen Therapeutics+6.55%-1.58%-1.32%+20.26%-60.00%VIRXViracta Therapeutics-11.56%-18.18%-10.00%-38.80%-97.50%Compare MarketRank™CompanyOverall ScoreAnalyst's OpinionShort Interest ScoreDividend StrengthESG ScoreNews and Social Media SentimentCompany OwnershipEarnings & ValuationENTOEntero TherapeuticsN/AN/AN/AN/AN/AN/AN/AN/AGLMDGalmed Pharmaceuticals0.3415 of 5 stars0.02.00.00.00.02.50.6QLGNQualigen TherapeuticsN/AN/AN/AN/AN/AN/AN/AN/AVIRXViracta Therapeutics2.0017 of 5 stars3.25.00.00.00.00.80.6Compare Analyst ForecastsCompanyConsensus Rating ScoreConsensus RatingConsensus Price Target% Upside from Current PriceENTOEntero Therapeutics 0.00N/AN/AN/AGLMDGalmed Pharmaceuticals 2.00HoldN/AN/AQLGNQualigen Therapeutics 0.00N/AN/AN/AVIRXViracta Therapeutics 2.33Hold$1.7511,337.91% UpsideCurrent Analyst Ratings BreakdownLatest VIRX, QLGN, GLMD, and ENTO Analyst RatingsDateCompanyBrokerageActionRatingPrice TargetDetails4/4/2025GLMDGalmed PharmaceuticalsMaxim GroupSubscribe to MarketBeat All Access for the recommendation accuracy ratingReiterated RatingBuy ➝ Hold(Data available from 6/19/2022 forward. View 10+ years of historical ratings with our analyst ratings screener.)Compare Sales & Book ValueCompanyAnnual RevenuePrice/SalesCashflowPrice/CashBook ValuePrice/BookENTOEntero TherapeuticsN/AN/AN/AN/A($0.82) per shareN/AGLMDGalmed PharmaceuticalsN/AN/AN/AN/A$9.87 per shareN/AQLGNQualigen Therapeutics$4.98M0.56N/AN/A($20.31) per share-0.18VIRXViracta TherapeuticsN/AN/AN/AN/A$0.33 per shareN/ACompare Profitability & EarningsCompanyNet IncomeEPSTrailing P/E RatioForward P/E RatioP/E GrowthNet MarginsReturn on Equity (ROE)Return on Assets (ROA)Next Earnings DateENTOEntero Therapeutics-$18.06MN/A0.00∞N/AN/A-1,063.82%-26.06%N/AGLMDGalmed Pharmaceuticals-$7.52M-$16.66N/A∞N/AN/A-32.21%-28.59%8/26/2025 (Estimated)QLGNQualigen Therapeutics-$13.42MN/A0.00∞N/AN/AN/A-424.18%7/1/2025 (Estimated)VIRXViracta Therapeutics-$51.06M-$1.10N/A∞N/AN/A-1,899.61%-114.21%8/12/2025 (Estimated)Latest VIRX, QLGN, GLMD, and ENTO EarningsDateQuarterCompanyConsensus EstimateReported EPSBeat/MissGap EPSRevenue EstimateActual RevenueDetails5/22/2025Q1 2025GLMDGalmed PharmaceuticalsN/A-$0.62N/A-$0.62N/AN/A5/15/2025Q1 2025ENTOEntero TherapeuticsN/A-$0.21N/A-$0.28N/AN/ACompare DividendsCompanyAnnual PayoutDividend Yield3-Year Dividend GrowthPayout RatioYears of Consecutive GrowthENTOEntero TherapeuticsN/AN/AN/AN/AN/AGLMDGalmed PharmaceuticalsN/AN/AN/AN/AN/AQLGNQualigen TherapeuticsN/AN/AN/AN/AN/AVIRXViracta TherapeuticsN/AN/AN/AN/AN/ACompare DebtCompanyDebt-to-Equity RatioCurrent RatioQuick RatioENTOEntero TherapeuticsN/A2.902.90GLMDGalmed PharmaceuticalsN/A9.029.02QLGNQualigen TherapeuticsN/A0.520.52VIRXViracta TherapeuticsN/A0.760.76Compare OwnershipInstitutional OwnershipCompanyInstitutional OwnershipENTOEntero Therapeutics12.30%GLMDGalmed Pharmaceuticals76.14%QLGNQualigen Therapeutics3.18%VIRXViracta Therapeutics31.37%Insider OwnershipCompanyInsider OwnershipENTOEntero Therapeutics0.75%GLMDGalmed Pharmaceuticals19.80%QLGNQualigen Therapeutics1.80%VIRXViracta Therapeutics10.69%Compare Miscellaneous StatsCompanyEmployeesShares OutstandingFree FloatOptionableENTOEntero Therapeutics94.77 million4.73 millionN/AGLMDGalmed Pharmaceuticals201.65 million1.33 millionNot OptionableQLGNQualigen Therapeutics50740,000723,000Not OptionableVIRXViracta Therapeutics2039.74 million35.50 millionOptionableVIRX, QLGN, GLMD, and ENTO HeadlinesRecent News About These CompaniesCalif. biotech company once worth $476M lays off every remaining employeeFebruary 11, 2025 | msn.comViracta Therapeutics Terminates Employees & Winds Down OperationsFebruary 8, 2025 | contractpharma.comViracta Therapeutics, Inc.: Viracta Therapeutics Announces Wind Down of OperationsFebruary 6, 2025 | finanznachrichten.deViracta Therapeutics Shuts Down Operations, Lays Off All StaffFebruary 6, 2025 | precisionmedicineonline.comViracta Therapeutics terminates employees, to wind down operationsFebruary 6, 2025 | markets.businessinsider.comViracta Therapeutics to cease operations and seek alternativesFebruary 5, 2025 | msn.comViracta Therapeutics Winds Down Operations, Terminates EmployeesFebruary 5, 2025 | marketwatch.comViracta Therapeutics hits end of the line, laying off all workers and winding downFebruary 5, 2025 | fiercebiotech.comViracta Therapeutics, Inc. Announces Employee Terminations and Wind Down of OperationsFebruary 5, 2025 | quiverquant.comViracta Therapeutics Announces Wind Down of OperationsFebruary 5, 2025 | globenewswire.comWhy Did Viracta Therapeutics Inc (VIRX) Stock Tumble -46.67% to $0.08?February 4, 2025 | bovnews.comVIRX stock plunges to 52-week low, touches $0.08February 3, 2025 | msn.comViracta Therapeutics to be delisted from NasdaqFebruary 3, 2025 | msn.comViracta Therapeutics strikes deal to avoid defaultJanuary 25, 2025 | msn.comViracta Therapeutics Inc (VIRX) Stock Trading RecapJanuary 10, 2025 | bovnews.comVIRX’s Unexpected Surge: What’s Next?January 6, 2025 | bovnews.comViracta Therapeutics Inc (VIRX) Stock Settles at $0.18: What’s Contributing to This Price Point?January 3, 2025 | bovnews.comCash-strapped Viracta ends phase 2 study of lead cancer drug as it mulls remaining optionsJanuary 3, 2025 | fiercebiotech.comLeerink Partners Issues Market Perform Rating for Viracta Therapeutics Inc (VIRX) StockDecember 30, 2024 | bovnews.comServiceTitan initiated, Viracta downgraded: Wall Street's top analyst callsDecember 27, 2024 | finance.yahoo.comNew MarketBeat Followers Over TimeMedia Sentiment Over TimeVIRX, QLGN, GLMD, and ENTO Company DescriptionsEntero Therapeutics NASDAQ:ENTO$0.48 +0.01 (+3.15%) Closing price 06/18/2025 03:59 PM EasternExtended Trading$0.48 0.00 (-0.47%) As of 06/18/2025 07:55 PM Eastern Extended trading is trading that happens on electronic markets outside of regular trading hours. This is a fair market value extended hours price provided by Polygon.io. Learn more.Entero Therapeutics, Inc., a clinical-stage biopharmaceutical company, engages in the development of targeted and orally delivered therapies for the treatment of patients with gastrointestinal diseases. The company's pipeline candidates include latiglutenase, a targeted oral biotherapeutic for celiac disease designed to breakdown gluten into non-immunogenic peptides, currently under Phase 2 studies; and capeserod, a selective 5-HT4 receptor partial agonist under Phase 1 studies for the treatment of gastroparesis. It is also involved in the development of adrulipase, a recombinant lipase enzyme designed to enable the digestion of fats and other nutrients, currently under Phase 2 studies for the treatment of exocrine pancreatic insufficiency in patients with cystic fibrosis and chronic pancreatitis; and niclosamide, an oral small molecule with anti-inflammatory inhibitor therapy, currently under Phase 2 studies for the treatment of ulcerative proctitis and ulcerative proctosigmoiditis, as well as immune checkpoint inhibitor-associated colitis and diarrhea in metastatic cancer patients. The company was formerly known as First Wave BioPharma, Inc. and changed its name to Entero Therapeutics, Inc. in May 2024. Entero Therapeutics, Inc. was incorporated in 2014 and is based in Boca Raton, Florida.Galmed Pharmaceuticals NASDAQ:GLMD$1.78 +0.11 (+6.59%) Closing price 06/18/2025 04:00 PM EasternExtended Trading$1.90 +0.12 (+6.97%) As of 06/18/2025 07:59 PM Eastern Extended trading is trading that happens on electronic markets outside of regular trading hours. This is a fair market value extended hours price provided by Polygon.io. Learn more.Galmed Pharmaceuticals Ltd., a biopharmaceutical company, focuses on the development of therapeutics for the treatment of liver diseases. It develops Aramchol, an oral therapy, which is in Phase III study for the treatment of non-alcoholic steato-hepatitis (NASH) in patients with overweight or obesity and who are pre-diabetic or type-II-diabetes mellitus. The company also evaluates Aramchol through ARRIVE Study, a Phase IIa clinical trial with HIV-associated non-alcoholic fatty liver disease and lipodystrophy. In addition, it engages in the development of Amilo-5MER, a 5 amino acid synthetic peptide methionine, threonine, alanine, aspartic acid, and valine. It has a license agreement with Samil Pharma. Co., Ltd. for the commercialization of Aramchol in the Republic of Korea; and a collaboration agreement with OnKai for its AI platform. Galmed Pharmaceuticals Ltd. was founded in 2000 and is headquartered in Tel Aviv, Israel.Qualigen Therapeutics NASDAQ:QLGN$3.75 +0.24 (+6.95%) As of 06/18/2025 03:58 PM Eastern This is a fair market value price provided by Polygon.io. Learn more.Qualigen Therapeutics, Inc., a biotechnology company, focuses on the development and commercialization of novel therapeutic products for the treatment of cancer and infectious diseases. It offers FastPack, a patent-protected rapid, onsite immunoassay testing system. The company is developing QN-302 for the treatment of pancreatic ductal adenocarcinoma; QN-247, an oligonucleotide-based drug candidate to treat various nucleolin-expressing cancers, including liquid and solid tumors; QN-165, a drug candidate for the potential broad-spectrum treatment of infectious diseases, such as COVID-19; RAS-F, a small-molecule RAS oncogene protein-protein inhibitor that blocks RAS mutations and inhibits tumor formation; and selective target antigen removal system, a therapeutic device to remove circulating tumor cells, viruses, inflammation factors, and immune checkpoints. Qualigen Therapeutics, Inc. was founded in 1996 and is based in Carlsbad, California.Viracta Therapeutics NASDAQ:VIRX$0.02 0.00 (-11.56%) As of 06/18/2025 01:55 PM EasternViracta Therapeutics, Inc., a clinical-stage precision oncology company, focuses on the treatment and prevention of virus-associated cancers that impact patients worldwide. Its lead product candidate is Nana-val, an all-oral combination therapy of its proprietary investigational drug, nanatinostat, and the antiviral agent valganciclovir. The company's Nana-val is in various ongoing clinical trials, including NAVAL-1, an open-label Phase 2 basket trial for the treatment of multiple subtypes of relapsed/refractory Epstein-Barr virus-positive (EBV+) lymphoma, as well as an open-label Phase 1b/2 trial for the treatment of EBV+ recurrent or metastatic nasopharyngeal carcinoma and other EBV+ solid tumors. Its product pipeline also includes vecabrutinib, a clinical-stage product candidate; and VRx-510, a preclinical product candidate. The company is headquartered in Cardiff, California. More Stock Comparisions from MarketBeat Stock Comparison Ideas (A-K)5GAgricultureAirlineAmerica FirstApparelArtificial IntelligenceAutomotiveBankBiotechBitcoinBlockchainBlue ChipCanadianCannabisCasinoChatGPTChineseCloud StorageCryptocurrencyCybersecurityDefenseDividendDow 30EcommerceElectric VehiclesEnergyEntertainmenteSportsEV ChargingFertilizerGoldGroceryGrowthHealthcareHigh DividendHotelStock Comparison Ideas (L-Z)Large CapLeisureLithiumMagnificent SevenMega CapMemeMetaverseMid CapMiningMusic IndustryNanotechnologyNFTNuclear EnergyOilPharmaceuticalQuantum ComputingRenewable EnergyRestaurantRetailSemiconductorSocial MediaSolarSpaceTechnologyTelecomToyUtilityVideo GameVirtual RealityWallStreetBets More Stock Ideas from MarketBeat Stock Lists 5G Stocks Biotech Stocks Blue Chip Stocks DOW 30 Stocks FAANG Stocks Gold Stocks Large Cap Stocks Lumber Stocks Marijuana Stocks Micro Cap Stocks Oil Stocks REITs Small Cap Stocks SPACs Travel Stocks Trillion Dollar Stocks Water Stocks Warren Buffett Stocks Low Priced Stocks Penny Stock List Popular Penny Stocks Top Stocks Today Stocks on Sale Stocks Under $0.05 Stocks Under $0.10 Stocks Under $0.25 Stocks Under $0.50 Stocks Under $1 Stocks Under $2 Stocks Under $3 Stocks Under $5 Stocks Under $10 Stocks Under $20 Stocks Under $30 Stocks Under $50 Stocks By Exchange NASDAQ Stocks NYSE Stocks NYSEAMERICAN Stocks NYSEARCA Stocks NYSEMKT Stocks OTCMKTS Stocks TSX Stocks TSXV Stocks LSE Stocks BATS Stocks Latest Stock Ideas Super Micro Computer Stock's Rally Backed by Strong Financials Forget the Fed: Home Depot Is the Real Gauge of the U.S. Consumer Analysts Keep Boosting Taiwan Semiconductor Stock—Here's Why Robinhood Director Sells Millions, But HOOD Stock Eyes Gains Coinbase Stock Pops as Senate Passes GENIUS Stablecoin Bill Chime’s Smart IPO: Half the Valuation, Double the Strength 3 Tech Stocks With High and Rising Institutional Interest Salesforce Raises Prices: 3 Reasons Its Stock Price Will Follow Get 30 Days of MarketBeat All Access for Free Sign up for MarketBeat All Access to gain access to MarketBeat's full suite of research tools. Start Your 30-Day Trial MarketBeat All Access Features Best-in-Class Portfolio Monitoring Get personalized stock ideas. Compare portfolio to indices. Check stock news, ratings, SEC filings, and more. Stock Ideas and Recommendations See daily stock ideas from top analysts. Receive short-term trading ideas from MarketBeat. Identify trending stocks on social media. Advanced Stock Screeners and Research Tools Use our seven stock screeners to find suitable stocks. Stay informed with MarketBeat's real-time news. Export data to Excel for personal analysis. Sign in to your free account to enjoy these benefits In-depth profiles and analysis for 20,000 public companies. Real-time analyst ratings, insider transactions, earnings data, and more. Our daily ratings and market update email newsletter. Sign in to your free account to enjoy all that MarketBeat has to offer. Sign In Create Account Your Email Address: Email Address Required Your Password: Password Required Log In or Sign in with Facebook Sign in with Google Forgot your password? Your Email Address: Please enter your email address. Please enter a valid email address Choose a Password: Please enter your password. Your password must be at least 8 characters long and contain at least 1 number, 1 letter, and 1 special character. Create My Account (Free) or Sign in with Facebook Sign in with Google By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.
